MicroIslet to Webcast Presentation at Rodman and Renshaw Techvest Healthcare Conference, November 8
November 03 2005 - 8:00AM
PR Newswire (US)
SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- MicroIslet Inc.
(AMEX:MII) announced that its President and COO Haro Hartounian,
Ph.D. will speak at the Rodman & Renshaw 7th Annual Techvest
Healthcare Conference on Tuesday, November 8th at 3:30 PM (EST) in
the Holmes II Room at the New York Palace Hotel in New York City.
MicroIslet is one of over 290 invited companies to present at this
conference, to be held November 7-9, 2005. MicroIslet is not only
seeking to free millions of insulin-dependent diabetics from daily
injections in the near term, but potentially to offer them a
curative treatment in the long term. In his presentation at the
conference, Dr. Hartounian will present the Company's innovative
strategy for using microencapsulated porcine islets to treat
insulin-dependent diabetes and its potential to reduce the
staggering $132 billion that the CDC estimates is spent each year
on diabetes-related healthcare. Highlights will include the
Company's stellar roster of Scientific Advisory Board members, its
strategic partnerships, including a unique islet supply partnership
with the Mayo Clinic, and the potential impact of the recently
enacted Pancreatic Islet Cell Transplant Act. A live webcast of the
presentation can be accessed by following the link for MicroIslet
on the "Conference Webcasting" page under "Upcoming Conferences" at
http://www.rodmanandrenshaw.com/, URL
http://wsw.com/webcast/rrshq7/mii/, or through the investor
relations section of the Company's website at
http://www.microislet.com/. Listeners are encouraged to visit the
Web site at least 15 minutes prior to the beginning of the
scheduled presentation to register and download and install any
necessary audio software. The presentation will be archived on the
same Web sites and available for a 90-day period. About MicroIslet
MicroIslet is a biotechnology company engaged in the research,
development, and commercialization of patented technologies in the
field of transplantation therapy for people with insulin-dependent
diabetes. MicroIslet's patented islet transplantation technology,
exclusively licensed from Duke University, includes methods for
isolating, culturing, cryopreservation, and immuno-protection
(microencapsulation) of islet cells. MicroIslet is working to
develop and commercialize a first product, called MicroIslet-P(TM),
a microencapsulated porcine islet cell suspension that will be used
for transplantation in patients with insulin-dependent diabetes.
Except for the historical information contained herein, the matters
set forth in this press release, including the anticipated benefits
of data from The Scripps Research Institute in guiding primate
studies of MicroIslet's microencapsulated porcine islet cell
suspension, the expectation of development of new therapeutic
products, and the impact of MicroIslet's products on diabetes
patients, are forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ
materially, including the risks and uncertainties inherent in
medical treatment discovery, development and commercialization, the
risks and uncertainties associated with MicroIslet's early stage
xenotransplantation technologies, the risks and uncertainties of
governmental approvals and regulation, MicroIslet's need to raise
substantial additional capital to execute its business plan, the
risks that MicroIslet's competitors will develop or market
technologies or products that are more effective or commercially
attractive than MicroIslet's products, and other risks detailed
from time to time in MicroIslet's most recent filings with the
Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. MicroIslet disclaims
any intent or obligation to update these forward-looking
statements. For more information, please visit our Web site at
http://www.microislet.com/. For further information, please
contact: Haro Hartounian, Ph.D., President and Chief Operating
Officer of MicroIslet, Inc., +1-858-657-0287, . DATASOURCE:
MicroIslet Inc. CONTACT: Haro Hartounian, Ph.D., President and
Chief Operating Officer of MicroIslet, Inc., +1-858-657-0287, Web
site: http://wsw.com/webcast/rrshq7/mii Web site:
http://www.rodmanandrenshaw.com/ Web site:
http://www.microislet.com/
Copyright
Microislet (AMEX:MII)
Historical Stock Chart
From May 2024 to Jun 2024
Microislet (AMEX:MII)
Historical Stock Chart
From Jun 2023 to Jun 2024